A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Nivolumab (Primary) ; Brentuximab vedotin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 30 Apr 2018 Planned number of patients changed from 85 to 82.
- 30 Apr 2018 Planned End Date changed from 1 Aug 2025 to 7 Aug 2024.
- 13 Nov 2017 Planned initiation date changed from 18 Aug 2017 to 18 Feb 2018.